Ac	acetylation
BC	breast cancer
BCSS	breast cancer-specific survival
BET	bromodomain and extra-terminal domain
BRD	bromodomain
CBP	CREB-binding protein
ChIP	chromatin immunoprecipitation
DDR	DNA damage response
DFS	disease-free survival
DIA	digital image analysis
ER	estrogen receptor
ESCC	esophageal squamous cell carcinoma
EMT	epithelial–mesenchymal transition
FDA	The Food and Drug Administration
HAT	histone acetyltransferase
HBV	hepatitis B virus
HCC	hepatocellular carcinoma
HDAC	histone deacetylase
HDI	histone deacetylase inhibitor
HNC	head and neck cancer
HNSCC	head and neck squamous cell carcinoma
IHC	immunohistochemistry
ING5	inhibitor of growth 5
K	lysine
KAT	lysine acetyltransferase
LSCC	lung squamous cell carcinoma
Me3	trimethylation
MLL1	mixed lineage leukemia 1
MFS	metastasis-free survival
NAD	nicotinamide adenine dinucleotide
NSCLC	non-small cell lung cancer
NSCLC	non-small cell lung cancer
OL	oral leukoplakia
OS	overall survival
OSCC	oral squamous cell carcinoma
PCA	prostate cancer
PFS	progression-free survival
PSA	prostate-specific antigen
PTMs	post-translational modifications
RB	retinoblastoma
SCLC	small cell lung cancer
SIRT	sirtuin
TF	transcription factor
TIP60	TAT-INTERACTIVE PROTEIN
TNBC	triple-negative breast cancer